Skip to main content
. Author manuscript; available in PMC: 2009 Jun 23.
Published in final edited form as: Cardiovasc Toxicol. 2008 Apr 30;8(2):57–69. doi: 10.1007/s12012-008-9015-1

Fig. 8.

Fig. 8

Quantitative analyses of ECHO images: LV mass was calculated in a blinded fashion, code was broken, and data tabulated. (a) I212N TGs only had an increase in LV mass following combination antiretroviral treatment. (b) H121N TGs without anti-retrovira1 treatment (HAART) had significant increase (∼25-50%) in LV mass from WT. (c) Y955C TGs also demonstrated an increase in LV mass (both vehicle and AZT-HAART treated) with an apparent additive impact in hearts from treated Y955C TGs. Data were normalized to body weight (mg/g) and plotted as mean ± SEM